C4 Therapeutics
CCCC
118 hedge funds and large institutions have $366M invested in C4 Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 26 closing their positions.
420% more call options, than puts
Call options by funds: $4.89M | Put options by funds: $941K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
30% more capital invested
Capital invested by funds: $281M → $366M (+$84.6M)
27% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 30
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
4.07% more ownership
Funds ownership: 88.49% → 92.56% (+4.1%)
3% more funds holding
Funds holding: 115 → 118 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17.2M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$15.4M |
| 3 |
Morgan Stanley
New York
|
+$7.15M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.56M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.5M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$5.9M |
| 3 |
Millennium Management
New York
|
-$2.93M |
| 4 |
Two Sigma Investments
New York
|
-$2.88M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.76M |
CCCC Hedge Fund Activity: Q3 2024 in Review
118 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2024, worth a combined $366M — up 30% from $281M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CCCC positions and 26 closed out — a net gain of 4 holders — while 38 added to existing stakes and 30 trimmed.
The largest buyer was OrbiMed, adding an estimated $17.2M. The largest seller was Balyasny Asset Management, cutting an estimated $11.5M.
- 118 institutional investors held C4 Therapeutics (CCCC) as of Q3 2024, up from 115 in Q2 2024.
- Funds reported $366M of C4 Therapeutics stock for Q3 2024, up 30% quarter-over-quarter.
- 30 funds opened new C4 Therapeutics positions in Q3 2024 and 26 closed out, a net change of +4 holders.
- The largest C4 Therapeutics buyer in Q3 2024 was OrbiMed, an estimated $17.2M added.
- The largest C4 Therapeutics seller in Q3 2024 was Balyasny Asset Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2024.